case_images: PMC9478540_01
case_images: Timeline from first visit to last follow-up.
case_images: fonc-12-953908-g001.jpg
case_images: PMC9478540_01_fonc-12-953908-g001.jpg
case_images: f1
case_images: A 56-year-old woman with no family or personal history of breast, ovarian, prostate, pancreatic, or gastric cancer was admitted to an oncological center in February 2018 because of pain in the epigastric area ( Figure 1 ).
case_images: (A) CT scan of S2 liver lesion, 10 mm in greatest dimension before talazoparib treatment (March 2019), (B) CT scan of S2 of the liver after 25 months of treatment without visual evidence of the disease (April 2021).
case_images: fonc-12-953908-g002.jpg
case_images: PMC9478540_01_fonc-12-953908-g002.jpg
case_images: f2
case_images: A complete clinical response had been achieved as of January 2021 ( Figures 2 ,  3 ): there were no signs of tumor lesions in the liver or signs of peritoneal carcinomatosis.
case_images: (A) CT scan of S6 liver lesion, 11 mm in greatest dimension before start of talazoparib treatment (March 2019), (B) CT scan of S6 of the liver after 25 months of treatment without visual evidence of the disease (April 2021).
case_images: fonc-12-953908-g003.jpg
case_images: PMC9478540_01_fonc-12-953908-g003.jpg
case_images: f3
case_images: A complete clinical response had been achieved as of January 2021 ( Figures 2 ,  3 ): there were no signs of tumor lesions in the liver or signs of peritoneal carcinomatosis.